How To Use HCPCS Code C9134

HCPCS code C9134 describes the specific medical procedure or service known as Factor XIII (antihemophilic factor, recombinant), tretten, per 10 i.u. This code is used to identify and bill for the administration of Factor XIII, a medication used to treat patients with Factor XIII deficiency, a rare bleeding disorder.

1. What is HCPCS C9134?

HCPCS code C9134 is a specific code used in medical coding to identify the administration of Factor XIII (antihemophilic factor, recombinant), tretten, per 10 i.u. This code is used to accurately document and bill for the use of this medication in the treatment of patients with Factor XIII deficiency.

2. Official Description

The official description of HCPCS code C9134 is “Factor XIII (antihemophilic factor, recombinant), tretten, per 10 i.u.” The short description for this code is “Enteral supp not otherwise c.” This description accurately represents the specific medication and dosage being administered.

3. Procedure

1. The procedure for administering Factor XIII (antihemophilic factor, recombinant) involves preparing the medication according to the manufacturer’s instructions.
2. The healthcare provider will then determine the appropriate dosage based on the patient’s weight and individual needs.
3. The medication is typically administered intravenously, following proper aseptic technique.
4. The provider will monitor the patient during and after the administration to ensure there are no adverse reactions or complications.
5. Documentation should include the date and time of administration, the dosage administered, and any relevant patient information.

4. When to use HCPCS code C9134

HCPCS code C9134 should be used when administering Factor XIII (antihemophilic factor, recombinant) to patients with Factor XIII deficiency. It is important to ensure that the patient meets the specific eligibility criteria for this treatment and that the administration is medically necessary.

5. Billing Guidelines and Documentation Requirements

When billing for HCPCS code C9134, healthcare providers should ensure that all necessary documentation is included to support the medical necessity of the treatment. This may include the patient’s medical history, diagnostic test results, and any other relevant information. It is also important to follow the specific billing guidelines set forth by Medicare or other insurance providers to ensure accurate and timely reimbursement.

6. Historical Information and Code Maintenance

HCPCS code C9134 was added to the Healthcare Common Procedure Coding System on January 1, 1985. It has a termination date of December 31, 2014. This code has not undergone any maintenance actions, as indicated by the action code N, which means no maintenance for this code. It is important for medical coders to be aware of the historical context and termination date of this code to ensure accurate coding and billing.

7. Medicare and Insurance Coverage

HCPCS code C9134 is covered by Medicare and other insurance providers. The pricing indicator code for this code is 57, which indicates that it is priced by other carriers. The multiple pricing indicator code is A, which means it is not applicable as HCPCS priced under one methodology. Healthcare providers should consult the Medicare Carriers Manual Reference Section Number 2130 for specific guidance on billing and reimbursement for this code.

8. Examples

Here are five examples of when HCPCS code C9134 should be billed:

1. A patient with diagnosed Factor XIII deficiency receives an intravenous administration of Factor XIII (antihemophilic factor, recombinant) at a healthcare facility.
2. A patient with a history of Factor XIII deficiency undergoes a surgical procedure and requires an intravenous administration of Factor XIII (antihemophilic factor, recombinant) during and after the procedure.
3. A patient with newly diagnosed Factor XIII deficiency begins regular intravenous administrations of Factor XIII (antihemophilic factor, recombinant) as part of their treatment plan.
4. A patient with a severe bleeding episode due to Factor XIII deficiency receives an emergency intravenous administration of Factor XIII (antihemophilic factor, recombinant) at an emergency department.
5. A patient with Factor XIII deficiency receives regular intravenous administrations of Factor XIII (antihemophilic factor, recombinant) as a prophylactic measure to prevent bleeding episodes.